Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Pharmacol.

Sec. Experimental Pharmacology and Drug Discovery

Systematic Review and Network Meta-Analysis of the Effects of Plant Active Substance on Quality of Life in Breast Cancer Patients

Provisionally accepted
Lu  WangLu Wang1Xiao Fan  XUXiao Fan XU2Mengmeng  GuoMengmeng Guo3Dong  YanxuDong Yanxu2Helin  DingHelin Ding2Alex  AlbertAlex Albert2shuai  haoshuai hao2Yuqing  SongYuqing Song2Jun  GuJun Gu2Zhenghong  YuZhenghong Yu1*
  • 1Jinling Clinical Medical College, Nanjing University of Chinese Medicine,Nanjing, China, Nanjing, China
  • 2Department of General Surgery, Nanjing General Hospital of Nanjing Military Command, Nanjing, China
  • 3Department of Breast Surgery, Nantong Maternal and Child Health Care, Nantong, China, Nantong, China

The final, formatted version of the article will be published soon.

Background: Plant-derived active substances are increasingly recognized as potential adjuvant therapies in breast cancer treatment, with emerging evidence suggesting their positive impact on both treatment outcomes and quality of life (QoL). This study aims to evaluate the effects of fifteen active substances—soy capsules, Helixor A, Viscum album [L.] extracts, Withania somnifera, Paullinia cupana, P. ovata husk, ginseng, curcumin, Jollab, ginger, fermented soybean extract, mistletoe extract, robuvit®, peppermint extract, and Chlorella extract—on QoL in patients with breast cancer (BC). Methods: A comprehensive literature search was performed across PubMed, EMBASE, Cochrane Library, and Web of Science up to January 2025. The primary outcomes of interest included QoL, fatigue, pain, physical functioning, nausea, and role and emotional functioning. Statistical analyses were carried out using StataMP 15.1 software. Treatment efficacy was assessed using Surface Under the Cumulative Ranking Curve (SUCRA) probabilities. Additionally, cluster analysis was conducted to examine the multidimensional effects of natural extracts across these seven clinical outcomes. Results: After screening, 18 eligible studies were included, encompassing 2062 patients and evaluating 15 substances. The analysis incorporated patient-reported outcomes from multiple trials: QoL (11 studies), fatigue (10 studies), pain (8 studies), physical functioning (8 studies), nausea (7 studies), role functioning (7 studies), and emotional functioning (7 studies). Based on SUCRA values, Withania somnifera was identified as the most effective treatment for enhancing QoL (99.4%)(SMD = 4.66, 95% CI: 3.47 to 5.85),physical functioning (100.0%)(SMD = 7.78, 95% CI: 6.61 to 8.96), role functioning (100.0%)(SMD = 8.10, 95% CI: 6.89 to 9.32), and emotional functioning (100.0%)(SMD = 5.71, 95% CI: 4.81 to 6.61)were more effective than the standard treatment. Moreover, Withania somnifera was found to be the most promising option for reducing fatigue (99.9%), pain (100.0%), and nausea (98.6%). This is a provisional file, not the final typeset article Conclusion: The network meta-analysis indicates that Withania somnifera was effective in enhancing quality of life and contributed to a reduction in therapeutic side effects in BC patients. Our findings support the therapeutic potential of plant bioactive substances in breast cancer care; however, further clinical validation of their efficacy is warranted.

Keywords: breast cancer, Plant active substance, Network meta-analysis, Quality of Life, randomized controlled trials

Received: 03 May 2025; Accepted: 30 Oct 2025.

Copyright: © 2025 Wang, XU, Guo, Yanxu, Ding, Albert, hao, Song, Gu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhenghong Yu, 13327800182@189.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.